Abiraterone acetate and cabazitaxel have shown an overall survival benefit in patients with metastatic castration-resistant prostate cancer following docetaxel failure.
Both have been approved in this indication. The search, follow-up and characterisation of circulating tumor cells should help for the response evaluation and the choice between the two treatments. Recently, alpharadin (radium-223 chloride) has demonstrated also an overall survival advantage in a large phase III trial. Other hormone therapies as MDV3100 or TAK700 are very promising. In undifferentiated cancers with neuroendocrine features, etoposide and platinum salts combinations have shown low efficiency.
Written by:
Beuzeboc P, Ropert S, Goldwasser F, Zerbib M. Are you the author?
Institut Curie, département d'oncologie médicale, 26, rue d'Ulm, 75005 Paris, France.
Reference: Bull Cancer. 2012 Apr 19. Epub ahead of print.
PubMed Abstract
PMID: 22516457